Application of Ero1alpha as pulmonary arterial hypertension biomarker and therapeutic target
By screening and verifying Ero1α as a biomarker of pulmonary arterial hypertension, products for screening, diagnosis and treatment were developed, which solved the problem that pulmonary arterial hypertension treatment drugs in the prior art cannot improve pulmonary vascular remodeling, and significantly alleviated pulmonary arterial hypertension. Development provides new therapeutic targets.
Patent Information
- Application Number
- CN202411190801.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-28
AI Technical Summary
Existing pulmonary hypertension treatment drugs can only temporarily relieve symptoms and cannot improve pulmonary vascular remodeling, resulting in a high mortality rate and lack of effective targets for abnormal biological behavior of pulmonary smooth muscle cells.
Ero1α was screened as a biomarker of pulmonary hypertension by protein spectrometry analysis, and its biological role in pulmonary hypertension was verified through cellular and animal experiments, and products for screening, diagnosis, treatment and monitoring were developed, including reducing Ero1α expression, including cellular and animal experiments. method of quantity.
The harmful effect of Ero1α in pulmonary hypertension was verified, and the development of pulmonary hypertension was significantly alleviated by knocking down Ero1α, providing new therapeutic targets, improving the mechanism of pulmonary vascular remodeling, and improving the survival rate of PH patients.
Smart Images

Figure CN119040449A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of detection and treatment of pulmonary hypertension, and in particular to an application of Ero1α as a biomarker and treatment target for pulmonary hypertension. Background Art
[0002] Pulmonary hypertension (PH) is a disease caused by a variety of reasons and characterized by pulmonary vasoconstriction and pulmonary vascular remodeling. The global incidence of PH is about 1%, and the incidence is as high as 10% in people over 65 years old. And the 7-year survival rate is only 49% from the date of right heart catheterization. Its high incidence and mortality make it urgent to study the pathophysiological mechanism of PH. The current targeted therapeutic drugs for PH (such as prostaglandins, phosphodiesterase-5 inhibitors, endothelin receptor antagonists and soluble guanylate cyclase stimulators) can improve patient symptoms and reduce hospitalization rates. However, the main effect of these targeted therapeutic drugs is to dilate blood vessels, which can only temporarily relieve symptoms, cannot improve pulmonary vascular remodeling, and cannot reduce the mortality of PH patients. Therefore, studying the pathogenesis of pulmonary vascular remodeling is a top priority to improve the survival rate of PH patients.
[0003] Pulmonary vascular remodeling is the central link in the pathogenesis of PH. Among them, the "tumor cell-like" characteristics of pulmonary artery smooth muscle cells (PASMCs): abnormal biological behaviors such as excessive proliferation and migration are the key causes of pulmonary vascular remodeling. Therefore, exploring the regulatory mechanism of abnormal biological behaviors of PASMCs is of great significance for improving pulmonary vascular remodeling and finding new therapeutic targets for PH.
[0004] In PASMCs involved in the pathogenesis of PH, multiple proteins such as Drp1, Survivin, and Rhi Kinase were found to be upregulated and promoted the development of PH, indicating that changes in protein expression levels in PASMCs have a crucial impact on the biological behavior of PASMCs. However, no scientific research team has yet conducted a comprehensive study on the protein expression levels in PASMCs involved in the pathogenesis of PH. Summary of the invention
[0005] In view of the shortcomings of the prior art, the present invention provides an application of Ero1α as a biomarker and therapeutic target for pulmonary hypertension, that is, a technology for comprehensively detecting and screening pulmonary hypertension biomarkers through protein spectrum analysis, and further exploring its biological role in pulmonary hypertension through cell experiments and animal experiments. To achieve the above purpose, the technical solution of the present invention is as follows:
[0006] In a first aspect, the present invention discloses a biomarker for pulmonary hypertension, wherein the biomarker is Ero1α gene or Ero1α protein;
[0007] In a second aspect, the present invention discloses an application of a biomarker for pulmonary hypertension, specifically:
[0008] The application includes at least one of (1)-(6):
[0009] (1) Application in the preparation of products for screening pulmonary hypertension;
[0010] (2) Use in the preparation of products for assessing the risk of pulmonary hypertension;
[0011] (3) Application in the preparation of products for diagnosing pulmonary hypertension;
[0012] (4) Use in the preparation of products for the treatment of pulmonary hypertension;
[0013] (5) Application in the preparation of products for monitoring the course of pulmonary hypertension;
[0014] (6) Application in the preparation of products for analyzing the prognosis of pulmonary hypertension.
[0015] Preferably, the product for treating pulmonary hypertension includes: a product that reduces the expression level of Ero1α.
[0016] The reagent is a reagent used to detect the expression amount of the biomarker.
[0017] It also includes a drug or a kit, comprising the biomarker according to claim 1, or a detection reagent or inhibitor thereof; the drug or the kit includes at least one of the uses described in (1) to (6) above.
[0018] Preferably, the product for treating pulmonary hypertension includes a product that reduces the expression level of Ero1α.
[0019] Also included is a method for screening the drug or kit as described above, wherein the screening is performed by detecting the difference in the expression level of Ero1α in the subject and the control group.
[0020] It also includes the use of Ero1α gene as a target gene in screening drugs for preventing, alleviating and / or treating pulmonary hypertension, wherein the screening is to screen for drugs that can inhibit the expression level of Ero1α gene or its expression product.
[0021] It also includes the use of Ero1α protein as a target in screening drugs for preventing, alleviating and / or treating pulmonary hypertension, wherein the screening is for substances that can reduce the activity of Ero1α protein.
[0022] It also includes the use of substances that inhibit Ero1α gene expression or reduce the expression level of its products in the preparation of drugs for preventing, alleviating and / or treating pulmonary hypertension. The substances that inhibit Ero1α gene expression include recombinant vectors or recombinant viruses that can knock down the Ero1α gene.
[0023] The present invention revolves around the Ero1α gene or the Ero1α protein it expresses as a biomarker for pulmonary hypertension (PH). Its application covers the entire process from screening, risk assessment, diagnosis, treatment, disease course monitoring to prognosis analysis, reflecting the broad potential of this biomarker in the development of PH-related products.
[0024] In the above scheme, the application of biomarkers is expanded as follows:
[0025] 1) Screening products: used to identify patients with pulmonary hypertension at an early stage, including blood test kits that can quickly detect Ero1α protein or its gene expression level.
[0026] 2) Risk assessment product: Helps assess an individual's risk of developing pulmonary hypertension by analyzing the correlation between Ero1α expression and risk.
[0027] 3) Diagnostic products: Used to diagnose pulmonary hypertension through highly specific Ero1α detection technology.
[0028] 4) Therapeutic products: Focus on reducing the expression of Ero1α to treat pulmonary arterial hypertension, including gene silencing therapy, small molecule inhibitors, etc.
[0029] 5) Disease course monitoring products: Track changes in the condition of patients with pulmonary arterial hypertension by regularly testing the expression level of Ero1α.
[0030] 6) Prognostic analysis product: Evaluate the prognosis of patients with pulmonary hypertension based on the relationship between Ero1α expression level and prognosis.
[0031] 7) Reagent and drug development: Reagents: reagents used to detect the expression level of Ero1α, including antibodies, probes, etc.; drugs or kits: containing Ero1α biomarkers or their detection reagents and inhibitors, used for the various applications mentioned above.
[0032] 8) Screening methods and applications: Screening methods, by detecting the difference in Ero1α expression levels in subjects, screen out effective drugs or kits; drug screening applications, using Ero1α gene as the target gene, screen for drugs or substances that can inhibit its expression or reduce the activity of its products.
[0033] 9) Strategies for inhibiting Ero1α expression: Substances that inhibit Ero1α gene expression, including recombinant vectors or recombinant viruses that can knock down the Ero1α gene, provide a new approach for the treatment of pulmonary arterial hypertension.
[0034] This invention not only reveals the importance of Ero1α in pulmonary hypertension, but also provides a theoretical basis for the development of related diagnostic and therapeutic products, demonstrating the potential for transformation from basic research to clinical application.
[0035] The technical principles of the present invention are as follows:
[0036] In order to fully explore the proteins in PASMCs that may affect their biological behavior, the present invention simultaneously subjected rat PASMCs cultured in normoxic and hypoxic conditions to data-independent protein spectrum analysis (DIA) to screen for proteins that were upregulated in PASMCs cultured in hypoxia. Subsequent qRT-PCR and Western blot verification revealed the most significantly upregulated protein in PASMCs cultured in hypoxia: endoplasmic reticulum oxidoreductase 1 (Ero1α). Cell experiments confirmed that knocking down Ero1α could reduce the proliferation and migration levels of PASMCs under normoxic and hypoxic culture, while overexpression of Ero1α caused the opposite effect. Animal experiments confirmed that knocking down Ero1α could significantly alleviate pulmonary hypertension caused by hypoxia and MCT. This indicates that Ero1α is a key molecule that promotes excessive proliferation and migration of PASMCs, thereby causing pulmonary vascular remodeling and ultimately leading to the occurrence and development of pulmonary hypertension. This reveals the key new target of the central environment for the onset of pulmonary hypertension and will provide an important basis for the prevention and treatment of pulmonary hypertension.
[0037] The advantages and beneficial effects of the present invention are as follows:
[0038] 1. Comprehensive exploration of protein expression of pulmonary artery smooth muscle cells under hypoxia: The present invention comprehensively reveals the up-regulated and down-regulated proteins in hypoxic pulmonary artery smooth muscle cells through protein spectrum analysis, which is of great significance for understanding the "tumor cell-like" characteristics of pulmonary artery smooth muscle cells under hypoxia - excessive proliferation and migration.
[0039] 2. The most significantly upregulated molecule in hypoxic pulmonary artery smooth muscle cells under hypoxia was found: The most significantly upregulated molecule in hypoxic pulmonary artery smooth muscle cells under hypoxia was verified by experimental techniques such as qRT-PCR and Western blot: Ero1α. The Ero1α gene was discovered in 1998, and its research history is only more than 20 years. There are few studies on the biological functions of this molecule, and they are mainly focused on tumor diseases. This invention confirms for the first time that Ero1α is the most significantly upregulated molecule in hypoxic pulmonary artery smooth muscle cells under hypoxia.
[0040] 3. Verification of the harmful effects of Ero1α in pulmonary hypertension: The present invention confirms that Ero1α is highly expressed in hypoxic pulmonary artery smooth muscle cells, and pulmonary artery smooth muscle cells show excessive proliferation and migration levels under hypoxic conditions, while knocking down Ero1α can reduce the proliferation and migration levels of pulmonary artery smooth muscle cells. At the same time, Ero1α is highly expressed in lung tissues with hypoxia and MCT-induced pulmonary hypertension, and is also highly expressed in the pulmonary arteries of human chronic obstructive pulmonary disease and pulmonary hypertension. Knocking down the expression of Ero1α in lung tissues by transfecting adeno-associated viruses significantly alleviates hypoxia and MCT-induced pulmonary hypertension. That is, the present invention conducts dual explorations from cell experiments and animal experiments, verifying that Ero1α promotes the development of pulmonary hypertension, and knocking down the expression of Ero1α can significantly alleviate the development of pulmonary hypertension.
[0041] In summary, the present invention comprehensively explored the protein expression levels of pulmonary artery smooth muscle cells under hypoxia through high-throughput sequencing technology, and determined through subsequent qRT-PCR and Western blot verification that Ero1α is the most significantly upregulated molecule in hypoxic pulmonary artery smooth muscle cells under hypoxia. Further cell and animal experiments confirmed that the high expression of Ero1α promotes the occurrence and development of pulmonary hypertension, and Ero1α is expected to become a new potential target in the treatment of pulmonary hypertension. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 This is a schematic diagram of the present invention, in which: hypoxia causes an increase in the expression level of Ero1α in pulmonary artery smooth muscle cells, thereby causing the enhancement of the proliferation and migration levels of pulmonary artery smooth muscle cells, which in turn causes the thickening of pulmonary arteriolar vessels, and ultimately causes the occurrence and development of pulmonary hypertension. Hypoxia: hypoxia, PASMC: pulmonary artery smooth muscle cells, ER: endoplasmic reticulum, Nucleus: cell nucleus, Proliferation: proliferation, Migration: migration, Pulmonary arteriole: pulmonary arteriole, Vascular remodelling: vascular remodeling, Vascular thickening: vascular thickening.
[0043] Figure 2 The screening process and expression verification of Ero1α of the present invention, including: (A) protein spectrum DIA (Data Independent Acquisition) detection and analysis flow chart, normoxia (21% O2) and hypoxia (2% O2) culture time are 24h; (B) DIA protein volcano map: hypoxia up-regulated and down-regulated proteins; (C) 10 proteins heat map with the most significant hypoxia up-regulated in DIA identification results; (D) qRT-PCR detection of protein mRNA expression levels in PASMCs in the heat map, n = 3; (E) Western blot detection of Ero1α expression levels in PASMCs under hypoxia (2% O2) culture, representative graph and (F) statistical graph, n = 5; *p < 0.05, **p < 0.01, ***p < 0.001. Normoxia: normoxia, Hypoxia: hypoxia.
[0044] Figure 3 The knockdown of Ero1α in the present invention reduces the proliferation and migration levels of PASMCs, wherein: (A) Representative graph and (B) statistical graph of Western blot verification that si-Ero1α knocks down the expression level of PASMCs under normoxia and hypoxia (2% O2, 24h); (C) Representative graph and (D) statistical graph of EdU staining detection of PASMCs proliferation level, magnification: 100 times; (E) Transwell detection of PASMCs migration level, representative graph and (F) statistical graph, magnification: 200 times, n=3; *p<0.05, **p<0.01, ***p<0.001. Normoxia+si-NC: normoxia+si-NC, Normoxia+si-Ero1α: normoxia+si-Ero1α, Hypoxia+si-NC: hypoxia+si-NC, Hypoxia+si-Ero1α: hypoxia+si-Ero1α.
[0045] Figure 4The present invention overexpressed Ero1α to increase the proliferation and migration levels of PASMCs, wherein: (A) Western blot verified that the Ero1α overexpression plasmid increased the expression level of PASMCs under normoxia and hypoxia (2% O2, 24h) in a representative figure and (B) statistical figure; (C) EdU staining detected the proliferation level of PASMCs in a representative figure and (D) statistical figure, magnification: 100 times; (E) Transwell detected the migration level of PASMCs, representative figure and (F) statistical figure, magnification: 200 times, n = 3; *p < 0.05, **p < 0.01, ***p < 0.001. Normoxia + si-NC: normoxia + si-NC, Normoxia + si-Ero1α: normoxia + si-Ero1α, Hypoxia + si-NC: hypoxia + si-NC, Hypoxia + si-Ero1α: hypoxia + si-Ero1α.
[0046] Figure 5 The present invention shows the expression difference of Ero1α in the high-pressure group and the control group in the human COPD-PH sample, rat hypoxic pulmonary hypertension (Rat HPH sample) and rat MCT-induced pulmonary hypertension (Rat MCT-PH sample) models, wherein: (A) immunofluorescence detection of the expression level of Ero1α in the pulmonary artery of the COPD-PH control and the patient, magnification: 400 times; (B) immunofluorescence detection of the expression level of Ero1α in the pulmonary artery of the normoxic control and hypoxic hypertensive group in the rat HPH model, magnification: 400 times; (C) immunofluorescence detection of the expression level of Ero1α in the pulmonary artery of the control and the high-pressure group in the rat MCT-PH model, magnification: 400 times. Control: control, COPD-PH: COPD-PH group, HPH: hypoxic pulmonary hypertension group, MCT-PH: MCT pulmonary hypertension group.
[0047] Figure 6The present invention knocks down the expression of Ero1α in lung tissue to alleviate HPH, wherein: (A) HPH modeling flow chart; (B) eGFP-labeled AAV was detected by upright fluorescence microscopy after frozen section of lung tissue, and the results showed that AAV infected the pulmonary artery as expected, magnification: 400 times; (C) RVSP pressure measurement representative graph; (D) HE-stained pulmonary arteriole representative graph, magnification: 200 times; (E) RVSP statistical graph; (F) pulmonary artery thickening index statistical graph, pulmonary artery thickening index = (outer diameter - inner diameter) / outer diameter, artery diameter in μm; (G) right ventricular hypertrophy index statistical graph; (H) cardiac output statistical graph; (I) total pulmonary resistance statistical graph, total pulmonary resistance = 80 × RVSP (mmHg) / pulmonary circulation blood flow (L / min), unit is dyn·s·cm -5 ; (J) Systemic circulation pressure statistics. HNO: normoxic group, HHO: hypoxic group, HNV: hypoxia + AAV-CTL (control) group, HAVP: hypoxia + AAV-Ero1α (prevention) group, HAVT: hypoxia + AAV-Ero1α (treatment) group. n = 8-10, ns: no statistical difference, ***p < 0.001.
[0048] Figure 7 The present invention knocks down the expression of Ero1α in lung tissue to alleviate MCT-PH, wherein: (A) MCT-PH modeling flow chart; (B) eGFP-labeled AAV was detected by upright fluorescence microscopy after frozen section of lung tissue, and the results showed that AAV infected the pulmonary artery as expected, magnification: 400 times; (C) RVSP pressure measurement representative graph; (D) HE-stained pulmonary arteriole representative graph, magnification: 200 times; (E) RVSP statistical graph; (F) pulmonary artery thickening index statistical graph, pulmonary artery thickening index = (outer diameter - inner diameter) / outer diameter, artery diameter in μm; (G) right ventricular hypertrophy index statistical graph; (H) cardiac output statistical graph; (I) total pulmonary resistance statistical graph, total pulmonary resistance = 80 × RVSP (mmHg) / pulmonary circulation blood flow (L / min), unit is dyn·s·cm -5 ; (J) Systemic circulation pressure statistics, MNC: ethanol saline group, MCT: MCT group, MNV: MCT+AAV-CTL group, MAV: MCT+AAV-Ero1α group, n=8-10, ns: no statistical difference, ***p<0.001. DETAILED DESCRIPTION
[0049] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments.
[0050] Example 1: Cell experiment
[0051] (1) Screening of proteins whose expression is upregulated under hypoxic culture of PASMCs.
[0052] 1) Protein spectrum analysis: The protein spectrum DIA analysis was performed on rat PASMCs cultured in normoxia (21% O2, 24h) and hypoxia (2% O2, 24h). Figure 2 A), proteins with increased and decreased expression under hypoxia are shown in the volcano plot ( Figure 2 B). The DIA process is based on the following three steps: The first step is to build a spectral library: The spectral library collects all detectable non-redundant high-quality peptide information (MS / MS spectra) of the sample as a peptide identification template for subsequent data analysis. It contains fragment ion intensities and retention times that describe the characteristics of peptide spectral peaks. The spectral library is constructed using data collected by data dependent acquisition (DDA) detection of samples of interest. The second step is to obtain a large amount of sample data in DIA mode: Data independent acquisition (DIA, also known as SWATH) mode uses the latest high-resolution mass spectrometry to simultaneously collect peptide ion features in terms of mass number and retention time. The third step is data analysis: By deconvolving the DIA data and combining it with the DDA spectral library, qualitative and quantitative information on peptides and proteins is obtained. The MSstats package is used to perform differential analysis on the data.
[0053] 2) qRT-PCR further screening: Based on fold change>5, p<0.05 under hypoxia, 10 proteins with the highest expression up-regulated under hypoxia were initially screened out ( Figure 2 C) and analyzed by qRT-PCR ( Figure 2 D) Verify the mRNA expression levels of these 10 proteins. The results show that the expression levels of Ero1α, Slc2a1, and Fam162a are significantly increased under hypoxia, and the expression level of Ero1α is the most significantly increased. The specific experimental process is as follows: Total RNA was extracted from rat PASMCs using TRIzol (TAKARA 9109). Reverse transcription was performed using the TaKaRa RR036A kit to synthesize cDNA, and then quantitative real-time polymerase chain reaction (qRT-PCR) was performed using the TaKaRa RR420A kit. Application 2 -ΔΔCtThe primer sequences used were as follows: Ero1α-forward: 5'-TGG ACG AAT CTC TGA GTG AGG-3', Ero1α-reverse: 5'-CAG CAT CGG GGG ACTGTA T-3'; Loxl2-forward: 5'-CCT ATA AGC CGG AGC AAC CC-3', Loxl2-reverse: 5'-AGA CGGTAC CCC ATT CTC CA-3'; Slc2a1-forward: 5'-CTT ATT GCC CAG GTG TTC GG-3', Slc2a1-reverse: 5'-GGC AGA AGG GCA ACA GGA TA-3'; Fam162a-forward: 5'-TGA GGG CAA GAA GCT TGAAC-3', Fam162a-reverse: 5'-TAC GTC TAG TCC GCT TTG GC-3'; Slc30a6-forward: 5'-GCC TGAGAT ACA CAC GGG AAG-3', Slc30a6-reverse: 5'-CTG CCA CAT GCT CTT GAA GC; Abcc10-forward: 5'-GGG GCC ACT TAC AGG TTTGA-3', Abcc10-reverse: 5'-AAC CAC TGC ATC GTG GCA TA-3'; Cdca5-forward: 5'-AAG GTT CCT GAG ATC ACG TCT T-3', Cdca5-reverse: 5'-ACG TCG GAGTCC TTA GGT TC-3'; Pros1-forward: 5'-CCC GAA ACG GAT TAT TTT TAT CCA-3', Pros1-reverse: 5'-TGG TCT GGG ATG GCA TTG AC-3'; Tbc1d7-forward: 5'-AGA TGG TGG AAG ACA GCGTG-3', Tbc1d7-reverse: 5'-AAA GCC TTG GGC AGC TGA G-3'; Rab29-forward: 5'-GGG ATA TTGCAG GGC AGG AG-3', Rab29-reverse: 5'-TGA TGA CAC AGG CAG AAG CA-3'.
[0054] 3) Western blot verification: Western blot was used to verify the expression of Ero1α in PASMCs cultured under hypoxia ( Figure 2 Middle E, Figure 2Middle F), the results showed that Ero1α was the most significantly upregulated protein in PASMCs cultured under hypoxia, and the expression level was highest at 24 h of hypoxia. Subsequent hypoxic culture was carried out under 2% O2 and 24 h of hypoxia as the hypoxic culture conditions.
[0055]
[0056] The amino acid sequence of Ero1α protein is as follows: >NP_612537.1 ERO1-like protein alpha precursor [Rattus norvegicus] MGRAWGLLVGLLGVVWLLRLGHGEERRPETAAQRCFCQVSGYLDDCTCDVE TIDKFNNYRLFPRLQKLLESDYFRYYKVNLRKPCPFWNDINQCGRRDCAVKPCHSDEVPDGIKSASYKYSKEANLLEECEQAERLGAVDESLSEETQKAVLQWTKHDDSSDSFCEVDDIQSPDAEYVDLLLNPERYTGYKGPDAWRIWSVIYEENCFKPQTIQRPLASGQGKHKENTFYSWLEGLCVEKRAFYRLISGLHASINVHLSARYLLQDNWLEKKWGHNVTEFQQRFDGVLTEGEGPRRLKNLYFLYLIELRALSKVLPFFERPDFQLFTGNKVQDVENKELLLEILHEVKSFPLHFDENSFFAGDKHEAHKLKEDFRLHFRNISRIMDCVGCFKCRLWGKLQTQGLGTALKILFSEKLIANMPESGPSYEFQLTRQEIVSLFNAFGRISTSVRELENFRHLLQNVH (SEQ ID NO.2).
[0057] Western blot detection steps are as follows: Total protein was extracted from PASMCs using a lysis buffer containing RIPA, protease inhibitors, and phosphatase inhibitors. Protein samples were electrophoresed on a 10% SDS-polyacrylamide gel and separated at 60mV until the marker was separated, and then separated at 120mV until the separation was complete. The gel containing the protein was transferred to a PVDF membrane in a transfer buffer at 250mA for 2 hours. The PVDF membrane was blocked with 5% skim milk powder for 1 hour at room temperature and then rinsed with TBST for 30 minutes (3 times, 10 minutes each time). The membrane was incubated with primary antibody on a shaker at 4°C overnight. The next day, the membrane was rinsed with TBST for 30 minutes (3 times, 10 minutes each time) and then incubated with secondary antibody diluted in 5% skim milk powder for 1 hour at room temperature. Subsequently, it was rinsed again with TBST for 15 minutes (3 times, 5 minutes each time), and then the protein bands were visualized and photographed. Antibodies used included Ero1α (Proteintech, Cat. No. 12007-1-AP) and Actin (Proteintech, Cat. No. 23660-1-AP).
[0058] (2) Verify whether knocking down Ero1α can attenuate the proliferation and migration levels of PASMCs.
[0059] 1) Cell treatment:
[0060] The protein expression level of Ero1α was knocked down by transfection of small interfering RNA (siRNA). PASMCs were evenly planted in six-well plates, and si-NC and si-Ero1α were transfected after 24 hours. The medium was changed 24 hours after transfection, and the culture plates of the hypoxia group were placed in a hypoxic (2% O2) incubator. The culture plates of the normoxic group continued to be cultured in a normoxic environment, and the cells were collected after 24 hours. The siRNA sequence targeting Ero1α is 5'-GCAAGCATCAATGTACATT-3'. In each well of the six-well plate, the transfection mixture included 900μL of complete culture medium, 50μL of Opti-MEM containing 2.5μL Lipofectamine 3000 (Lipo3000), and 50μL of Opti-MEM containing 2.5μL siRNA.
[0061] 2) Cell grouping:
[0062] Normoxia+si-NC, normoxia+si-Ero1α, hypoxia+si-NC, hypoxia+si-Ero1α.
[0063] 3) Detection indicators and methods:
[0064] ①EdU staining to detect cell proliferation level: RiboBio's EdU staining kit (Cell-LightTM EdUApollo567 In Vitro Kit) was used to detect the proliferation of PASMCs. Reagent A of the EdU staining reagent was diluted in complete cell culture medium at a ratio of 1:1000, and 100 μL of the diluted reagent was added to the seeded PASMCs in a 96-well plate. After incubation for 2 hours, the cells were fixed with 4% paraformaldehyde and then treated with 0.5% Triton X-100 to increase the permeability of the cell membrane. Subsequently, the cells were stained with Apollo for 30 minutes. After Apollo staining, the cells were treated again with 0.5% Triton X-100 to further increase the permeability and then stained with Hoechst 33342 for 30 minutes. To prevent fluorescence quenching, the staining images of PASMCs were taken using a fluorescence microscope immediately after staining.
[0065] ② Transwell assay for cell migration: PASMCs were seeded into 12-well plates and transfected with siRNA or plasmids. 24 hours after transfection, cells were digested and prepared into a 200 μL medium suspension containing 10,000 cells. 600 μL of complete medium (without cells) was added to the lower chamber of the Transwell (pore size 8 μm, Corning), and 200 μL of cell suspension was added to the upper chamber. After 24 hours, the cells were transferred to normoxic (normoxia group) or hypoxic (hypoxia group) conditions for another 24 hours, and then cell staining and photography were performed. The chamber was removed from the incubator, rinsed with phosphate-buffered saline (PBS), and then fixed with 4% paraformaldehyde (200 μL in the upper chamber and 800 μL in the lower chamber) for 20 minutes. The cells were then rinsed again with PBS and stained with 0.1% crystal violet (200 μL in the upper chamber and 800 μL in the lower chamber) for 20 minutes. The chamber was washed in PBS buffer until the washing solution became clear. Gently remove the non-migrated cells in the upper chamber with a cotton swab. Images of PASMCs that successfully migrated to the lower chamber were taken by optical microscopy.
[0066] 4) Experimental results: si-Ero1α transfection into PASMCs knocked down the expression of Ero1α under normoxia and hypoxia ( Figure 3 Middle A, Figure 3 Then, EdU staining was used to detect the proliferation level of PASMCs, and Transwell was used to detect the migration level of PASMCs. The results showed that PASMCs showed enhanced proliferation and migration under hypoxia, while knocking down Ero1α reduced the proliferation of PASMCs under normoxia and hypoxia ( Figure 3 Middle C, Figure 3 Middle D), migration level ( Figure 3 Middle E, Figure 3 Middle F).
[0067] (3) To verify whether overexpression of Ero1α enhances the proliferation and migration levels of PASMCs.
[0068] 1) Cell treatment:
[0069] The protein expression level of Ero1α was enhanced by transfecting plasmids. PASMCs were evenly planted in six-well plates, and 24 hours later, the control plasmid Ctrl and the Ero1α overexpression plasmid O-Ero1α were transfected respectively. The medium was changed 24 hours after transfection, and the hypoxia group culture plates were placed in a hypoxia (2% O2) incubator. The normoxic group culture plates continued to be cultured in a normoxic environment, and the cells were collected after 24 hours. The overexpression of Ero1α was achieved by transfecting the Ero1α overexpression plasmid. In each well of the six-well plate, the transfection mixture included 900 μL of complete culture medium, 50 μL of Opti-MEM containing 2.0 μL Lipofectamine 3000, and 50 μL of Opti-MEM containing 800 ng plasmid and 2.0 μL P3000 reagent.
[0070] 2) Cell grouping:
[0071] Normoxia+Ctrl, Normoxia+O-Ero1α, Hypoxia+Ctrl, Hypoxia+O-Ero1α.
[0072] 3) Detection indicators and methods:
[0073] ① Proliferation level: EdU staining was used to detect cell proliferation level; the specific experimental method was the same as the si-Ero1α transfection part.
[0074] ②Migration level: Transwell assay was used to detect cell migration level. The specific experimental method was the same as the above transfection of si-Ero1α.
[0075] 5) Experimental results: O-Ero1α transfection into PASMCs increased the expression of Ero1α under normoxia and hypoxia ( Figure 4 Middle A, Figure 4 Then, EdU staining was used to detect the proliferation level of PASMCs, and Transwell was used to detect the migration level of PASMCs. The results showed that PASMCs showed enhanced proliferation and migration under hypoxia, and overexpression of Ero1α further enhanced the proliferation of PASMCs under normoxia and hypoxia ( Figure 4 Middle C, Figure 4 D) and migration level ( Figure 4 Middle E, Figure 4 Middle F).
[0076] (4) Detect the expression level of Ero1α in three specimens: human COPD-PH, rat HPH, and rat MCT-PH.
[0077] 1) Specimen selection:
[0078] COPD-PH specimens: Lung tissues collected from COPD-PH patients and age- and sex-matched control patients. Lung cancer was excluded from both PH and controls.
[0079] HPH specimens: specimens from the high pressure group and control group of the previously established HPH animal model.
[0080] MCT-PH specimens: specimens from the high-pressure group and control group of the previously established MCT-PH animal model.
[0081] 2) Specimen processing:
[0082] The expression and localization of Ero1α in the pulmonary artery were detected by immunofluorescence staining. The immunofluorescence staining steps were as follows: the sections were baked in an oven at 60°C for 30-60 minutes, and then dewaxed by immersing them in xylene I for 20 minutes, xylene II for 20 minutes, anhydrous ethanol I for 10 minutes, anhydrous ethanol II for 5 minutes, 85% alcohol for 5 minutes, and 75% alcohol for 5 minutes. The sections were then rinsed with slowly flowing tap water, immersed in an antigen retrieval solution containing EDTA, heated to boiling in a high-heat microwave, cooled for 8 minutes, and repeated four times. After the sections cooled to room temperature, they were rinsed three times with PBS, blocked with goat / donkey serum for 40 minutes at room temperature, and then incubated with primary antibodies (α-SMA, BM0002, 1:200; Ero1α, Proteintech CatNo.12007-1-AP, 1:800) for 24 hours at 4°C. The next day, the sections were washed with PBS for 15 minutes, incubated with secondary antibodies for 50 minutes at room temperature, and the subsequent steps were performed in the dark to prevent light fluorescence quenching. The sections were washed with PBS for 15 minutes, stained with DAPI for 10 minutes, washed again with PBS, and mounted with neutral gum. To prevent fluorescence quenching, images were taken using a fluorescence microscope immediately after staining.
[0083] 3) Experimental results: In the specimens of the three models, the pulmonary arterioles in the pulmonary hypertension group were significantly thickened compared with the control group, and the expression level of Ero1α in the pulmonary arterioles in the hypertension group was significantly higher than that in human COPD-PH patients ( Figure 5 Middle A), previously established rat HPH model high pressure group ( Figure 5 Middle B), MCT-PH high pressure group of rats previously modeled ( Figure 5 C) were significantly higher than those in the control group, indicating that Ero1α is very likely to be involved in the development of PH at the animal level.
[0084] Example 2: Animal model experiment.
[0085] (1) To verify whether knocking down Ero1α can alleviate HPH.
[0086] 1) Modeling method:
[0087] Before the start of the animal experiment, adeno-associated virus AAV-Ero1α knocking down Ero1α and adeno-associated virus control AAV-CTL were constructed. Fifty male SD rats (weight 90-140g, 4 weeks old) were randomly divided into five groups. The rats were kept in a specific pathogen free (SPF) animal breeding center throughout the whole process. First, 4-week-old male SD rats were placed in the SPF breeding room for 1 week for isolation and quarantine and adaptation to the environment, and then AAV-CTL and AAV-Ero1α (prevention) were injected into the lung tissue of the corresponding group of rats through the airway. After the injection, the rats were kept for 2 weeks to wait for the injected AAV to be expressed in the lung tissue, and then the hypoxia process was started: except for the rats in the normoxic group, all rats were exposed to a 10% O2 hypoxic environment for 4 weeks, that is, continuous hypoxia for 28 days, hypoxia for 8 hours a day. After 2 weeks of hypoxia exposure (14th day of hypoxia), the rats in the treatment group were given airway injection of AAV-Ero1α (treatment), and then hypoxia continued until the 28th day, when the model was terminated.
[0088] 2) Experimental groups:
[0089] Normoxia group, hypoxia group, hypoxia+AAV-CTL (control) group,
[0090] Hypoxia + AAV-Ero1α (prevention) group, hypoxia + AAV-α (treatment) group.
[0091] 3) Detection indicators and methods:
[0092] ① Right ventricular systolic pressure was measured by right heart floating catheter; left carotid artery catheter was used to measure systemic circulation pressure; cardiac output was measured by thermodilution method and total pulmonary resistance (TPR) was calculated, TPR = 80 × RVSP (mmHg) / cardiac output (L / min), dyn·s·cm -5 .
[0093] ② Separate the right ventricle (RV) and left ventricle + ventricular septum (LV + Septum), dry and weigh them, and calculate the right ventricular hypertrophy index (RV / (LV + Septum)).
[0094] ③Separate the lung tissue, embed it in paraffin, cut white slices, and use them for:HE staining: calculate the vascular thickening index of pulmonary arterioles (diameter 50-200μm), and the thickening index calculation formula = [vascular outer diameter (μm)-vascular inner diameter (μm)] / (vascular outer diameter (μm)). HE staining steps are as follows: 1. Dewaxing: Soak the paraffin slices in xylene I for 20 minutes, then xylene II for 20 minutes, anhydrous ethanol I for 5 minutes, anhydrous ethanol II for 5 minutes, 75% alcohol for 5 minutes, and finally rinse with slowly flowing tap water. 2. Hematoxylin staining: The slices are stained in hematoxylin solution for 3-5 minutes, rinsed with tap water, differentiated with differentiation solution, rinsed with tap water again, blued with blueing solution, and rinsed with running water. 3. Eosin staining: The slices are dehydrated in 85% and 95% gradient alcohol for 5 minutes, and then stained in eosin solution for 5 minutes. 4. Dehydration and sealing: The sections were placed in anhydrous ethanol I, II, and III for 5 minutes each, and then in xylene I and II for 5 minutes each, until the tissue was transparent. Finally, the sections were sealed with neutral gum. After completing these steps, images were taken with an optical microscope for subsequent analysis.
[0095] ④ At the end of modeling, the lung tissues washed with saline were quickly frozen in liquid nitrogen, then embedded in OCT and frozen sections were performed, and the expression and localization of AAV virus in the lung tissues of each group were detected under an upright fluorescence microscope.
[0096] 4) Experimental results: The modeling process is shown in the figure ( Figure 6 As shown in A). Under an upright fluorescence microscope, AAV carrying enhanced green fluorescence (eGFP) can be observed to be expressed in the pulmonary artery as expected after transfection ( Figure 6 B). The analysis results after modeling are shown in the figure. Hypoxia caused an increase in the right ventricular systolic pressure (RVSP) of rats ( Figure 6 C, E), pulmonary arteriole thickening ( Figure 6 D, F), right ventricular hypertrophy ( Figure 6 Middle G), decreased cardiac output ( Figure 6 Middle H), total lung resistance increased ( Figure 6 In the prevention group and the treatment group, knocking down Ero1α significantly alleviated the above phenomenon. These results show that at the animal level, Ero1α promotes the occurrence and development of HPH, and knocking down Ero1α can significantly alleviate HPH. In addition, hypoxia did not cause an increase in systemic circulation pressure, and there was no statistical difference in systemic circulation pressure among the groups ( Figure 6 Middle J), indicating that pulmonary hypertension is not due to systemic hypertension causing the increased measured pressure.
[0097] (2) To verify whether knocking down Ero1α can alleviate MCT-PH.
[0098] 1) Modeling method:
[0099] Before the animal experiment began, adeno-associated virus AAV-Ero1α and adeno-associated virus control AAV-CTL for knocking down Ero1α were constructed. 40 male SD rats (weight 140-190g, 5 weeks old) were randomly divided into four groups. The rats were kept in a specific pathogen-free (SPF) breeding center throughout the whole process. After the 5-week-old rats entered the SPF breeding center, they were first kept for 1 week for quarantine and adaptation to the environment. At 6 weeks of age, AAV-CTL and AAV-Ero1α were injected through the airway in the corresponding groups. After the injection of AAV, the rats were kept for 2 weeks to wait for AAV to be expressed in the lung tissue of the injected rats. After 2 weeks, the rats were 8 weeks old. At this time, ethanol saline and monocrotaline (MCT) solution were injected intraperitoneally in the corresponding groups (ethanol: saline = 2:8 solvent, solute is MCT, MCT concentration is 1%, and the dose is 60 mg / kg). After the intraperitoneal injection of MCT solution, they were kept for 3 weeks to end the modeling.
[0100] 2) Experimental groups:
[0101] Ethanol saline group, MCT group, MCT+AAV-CTL group, and MCT+AAV-Ero1α group.
[0102] 3) Detection indicators and methods:
[0103] Same as HPH model.
[0104] 4) Experimental results: The modeling process is shown in the figure ( Figure 7 As shown in A). Under an upright fluorescence microscope, AAV carrying eGFP can be observed to be expressed in the pulmonary artery as expected after transfection ( Figure 6 The analysis results after modeling are shown in the figure. Intraperitoneal injection of MCT solution caused severe PH in rats, which was manifested by increased RVSP ( Figure 7 C, E), pulmonary arteriole thickening ( Figure 7 D, F), right ventricular hypertrophy ( Figure 7 Middle G), decreased cardiac output ( Figure 7 Middle H), total lung resistance increased ( Figure 7 I), while knocking down the expression of Ero1α significantly alleviated these phenomena. This indicates that Ero1α promotes the development of MCT-PH, and knocking down Ero1α can significantly alleviate MCT-PH. In addition, the increased pressure in the pulmonary hypertension group was not due to systemic hypertension, and there was no statistical difference in systemic circulation pressure between the groups ( Figure 7 (in J).
Claims
1. A use of a biomarker or a reagent for detecting the biomarker, characterized in that: The biomarker is Ero1α gene or Ero1α protein; The application includes at least one of (1) to (6): (1) Application in the preparation of products for screening pulmonary hypertension; (2) Use in the preparation of products for assessing the risk of pulmonary hypertension; (3) Application in the preparation of products for diagnosing pulmonary hypertension; (4) Use in the preparation of products for the treatment of pulmonary hypertension; (5) Application in the preparation of products for monitoring the course of pulmonary hypertension; (6) Application in the preparation of products for analyzing the prognosis of pulmonary hypertension.
2. The use according to claim 1, characterized in that: The product for treating pulmonary hypertension includes: a product for reducing the expression level of Ero1α.
3. The use according to claim 1, characterized in that: The reagent is a reagent for detecting the expression amount of the biomarker.
4. A drug or kit, characterized in that: The invention comprises the biomarker according to claim 1, or a detection reagent or inhibitor thereof; the drug or kit comprises at least one of the uses (1) to (6) as described in claim 1.
5. The drug or kit according to claim 4, characterized in that: The product for treating pulmonary hypertension includes a product that reduces the expression level of Ero1α.
6. A method for screening the drug or kit according to claim 4, characterized in that: Screening was performed by detecting the difference in Ero1α expression between the subjects and the control group.
7. Use of the Ero1α gene as a target gene in screening drugs for preventing, alleviating and / or treating pulmonary arterial hypertension, characterized in that: The screening is to screen for the ability to inhibit the expression level of the Ero1α gene or its expression product.
8. Use of Ero1α protein as a target in screening drugs for preventing, alleviating and / or treating pulmonary arterial hypertension, characterized in that: The screening is to screen for substances that can reduce the activity of Ero1α protein.
9. Use of a substance that inhibits Ero1α gene expression or reduces the expression level of its product in the preparation of a drug for preventing, alleviating and / or treating pulmonary arterial hypertension.
10. The use according to claim 9, characterized in that: The substance that inhibits the expression of the Ero1α gene includes a recombinant vector or a recombinant virus that can knock down the Ero1α gene.
Citation Information
Patent Citations
Novel cell lines and methods
CN102369275A
Application of ErbB3 as pulmonary arterial hypertension biomarker and therapeutic target
CN115976196A
Application of PLEKHH2 in diagnosis and treatment of pulmonary arterial hypertension
CN116983413A
